title: Brucellosis in dialysis patients. Does it exist?
abstract: BACKGROUND
  Brucellosis is a zoonotic disease transmittable to humans. It is diagnosed either by isolation of Brucella organism in culture of blood or other sample types (e.g., bone marrow or liver biopsy specimens), or by a combination of serological tests and clinical findings. Dialysis patients constitute a special population group with an impaired autoimmune system and a propensity to develop infections, such as brucellosis. This paper presents the high incidence of brucellosis in our dialysis patients during last year, while there was not any zoonotic infection recorded in the previous at least 5 year period.
  
  
  RESULTS
  This is a retrospective study including 8 dialysis patients, undergoing renal replacement therapies (5 patients were on hemodialysis (HD) and 3 on peritoneal dialysis (PD)), who out of a total of 124 patients developed brucellosis, during the last year. Four patients were male and four female and their mean age was 67 +/- 9 years. Clinical presentation of Brucellosis infection was mild with low-grade fever and symptoms of influenza. All patients were living in places where animal brucellosis was prevalent. Infection was diagnosed on the basis of clinical symptoms and signs and with polymerase chain reaction (PCR) analysis of peripheral blood. The affected patients had consumed fresh unpasteurized milk and cheese and were treated with oral doxycycline and oral rifampicin for 6 weeks. All patients are in follow up for at least 1 year, during which there were no relapses.
  
  
  CONCLUSIONS
  Brucellosis is a zoonotic disease that can occur in dialysis patients who are susceptible to infection under certain conditions. Our brucellosis patients lived in agricultural and veterinary areas and had consumed unpasteurized milk and cheese and insufficiently cooked meat derived from infected animals.
authors.affiliation: Division of Nephrology, Democritus University of Thrace, University Hospital of Alexandroupolis, Kolokotroni 15, Alexandroupolis, Greece. Polych@med.duth.gr
authors.forename: K
authors.initials: K
authors.lastname: Kantartzi
authors.forename: S
authors.initials: S
authors.lastname: Panagoutsos
authors.forename: V
authors.initials: V
authors.lastname: Kokkinou
authors.forename: E
authors.initials: E
authors.lastname: Alepopoulou
authors.forename: E
authors.initials: E
authors.lastname: Mourvati
authors.forename: P
authors.initials: P
authors.lastname: Passadakis
authors.forename: V
authors.initials: V
authors.lastname: Vargemezis
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002002:Brucella / Q000302:isolation & purification; D002006:Brucellosis / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D004318:Doxycycline / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012189:Retrospective Studies; D012293:Rifampin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D004318:Doxycycline; D012293:Rifampin